Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CRIZANLIZUMAB-TMCA Cause Infusion related reaction? 110 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Infusion related reaction have been filed in association with CRIZANLIZUMAB-TMCA. This represents 9.7% of all adverse event reports for CRIZANLIZUMAB-TMCA.

110
Reports of Infusion related reaction with CRIZANLIZUMAB-TMCA
9.7%
of all CRIZANLIZUMAB-TMCA reports
0
Deaths
46
Hospitalizations

How Dangerous Is Infusion related reaction From CRIZANLIZUMAB-TMCA?

Of the 110 reports, 46 (41.8%) required hospitalization, and 2 (1.8%) were considered life-threatening.

Is Infusion related reaction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CRIZANLIZUMAB-TMCA. However, 110 reports have been filed with the FAERS database.

What Other Side Effects Does CRIZANLIZUMAB-TMCA Cause?

Pain (313) Sickle cell anaemia with crisis (263) Back pain (125) Arthralgia (81) Pain in extremity (75) Drug ineffective (74) Chest pain (63) Pyrexia (62) Nausea (57) Fatigue (55)

What Other Drugs Cause Infusion related reaction?

INFLIXIMAB (12,946) RITUXIMAB (11,871) TOCILIZUMAB (8,340) METHOTREXATE (7,225) ADALIMUMAB (6,865) ABATACEPT (6,759) PREDNISONE (6,481) LEFLUNOMIDE (6,205) HYDROXYCHLOROQUINE (5,991) ETANERCEPT (5,960)

Which CRIZANLIZUMAB-TMCA Alternatives Have Lower Infusion related reaction Risk?

CRIZANLIZUMAB-TMCA vs CRIZOTINIB CRIZANLIZUMAB-TMCA vs CROFELEMER CRIZANLIZUMAB-TMCA vs CROMOLYN CRIZANLIZUMAB-TMCA vs CROTALIDAE POLYVALENT IMMUNE FAB CRIZANLIZUMAB-TMCA vs CUBICIN

Related Pages

CRIZANLIZUMAB-TMCA Full Profile All Infusion related reaction Reports All Drugs Causing Infusion related reaction CRIZANLIZUMAB-TMCA Demographics